Can Adiponectin Help us to Target Diastolic Dysfunction?

[1]  T. Cascino,et al.  Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction , 2017, Current Hypertension Reports.

[2]  I. Komuro,et al.  Relationship of Left Ventricular Diastolic Function to Obesity and Overweight in a Japanese Population With Preserved Left Ventricular Ejection Fraction. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[3]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[4]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[5]  A. Darzi,et al.  The Effects of Bariatric Surgery on Cardiac Structure and Function: a Systematic Review of Cardiac Imaging Outcomes , 2016, Obesity Surgery.

[6]  D. Ramji,et al.  Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets , 2015, Cytokine & growth factor reviews.

[7]  A. Gavazzi,et al.  Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use , 2015, European journal of heart failure.

[8]  A. Nelson,et al.  Effect of 12 Weeks of Periodized Resistance Training Upon Total Plasma Adiponectin Concentration in Healthy Young Men , 2015, Journal of strength and conditioning research.

[9]  T. Best,et al.  Heart failure with preserved ejection fraction: Defining the function of ROS and NO. , 2015, Journal of applied physiology.

[10]  Jia-Rong Wu,et al.  Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review , 2015, Heart Failure Reviews.

[11]  Roy Taylor,et al.  High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial , 2015, Diabetologia.

[12]  Rui Li,et al.  AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. , 2015, American journal of physiology. Endocrinology and metabolism.

[13]  A. Leite-Moreira,et al.  Association between plasma leptin and adiponectin levels and diastolic function in the general population , 2015, Expert opinion on therapeutic targets.

[14]  M. Fischer,et al.  Successful weight reduction improves left ventricular diastolic function and physical performance in severe obesity. , 2015, International heart journal.

[15]  G. Biondi-Zoccai,et al.  Heart failure with preserved ejection fraction: refocusing on diastole. , 2015, International journal of cardiology.

[16]  H. Randeva,et al.  Differential Effects of Leptin and Adiponectin in Endothelial Angiogenesis , 2015, Journal of diabetes research.

[17]  Li Li,et al.  Adiponectin reduces carotid atherosclerotic plaque formation in ApoE−/− mice: Roles of oxidative and nitrosative stress and inducible nitric oxide synthase , 2014, Molecular medicine reports.

[18]  J. George,et al.  The multifaceted and controversial immunometabolic actions of adiponectin , 2014, Trends in Endocrinology & Metabolism.

[19]  H. Blundell,et al.  Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. , 2014, Human reproduction.

[20]  S. Legrand-Poels,et al.  Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. , 2014, Diabetes research and clinical practice.

[21]  A. Shah,et al.  Redox regulation of cardiac hypertrophy. , 2014, Journal of molecular and cellular cardiology.

[22]  D. Mary,et al.  Effect of monomeric adiponectin on cardiac function and perfusion in anesthetized pig. , 2014, The Journal of endocrinology.

[23]  Rahul C. Deo,et al.  Phenotypic spectrum of heart failure with preserved ejection fraction. , 2014, Heart failure clinics.

[24]  C. Jenkinson,et al.  The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus , 2014, Acta Diabetologica.

[25]  I. Komuro,et al.  Angiogenesis and Cardiac Hypertrophy: Maintenance of Cardiac Function and Causative Roles in Heart Failure , 2014, Circulation research.

[26]  E. Kranias,et al.  The role of CaMKII regulation of phospholamban activity in heart disease , 2014, Front. Pharmacol..

[27]  A. Akintunde,et al.  Carotid atherosclerosis and right ventricular diastolic dysfunction in a sample of hypertensive Nigerian patients , 2013, Croatian medical journal.

[28]  M. Pall.  The NO/ONOO-Cycle as the Central Cause of Heart Failure , 2013, International journal of molecular sciences.

[29]  K. Matsuda,et al.  A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity , 2013, Nature.

[30]  H. Anders,et al.  The immune system and kidney disease: basic concepts and clinical implications , 2013, Nature Reviews Immunology.

[31]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[32]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.

[33]  Martijn A Spruit,et al.  Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[34]  D. McManus,et al.  Relations of Circulating Resistin and Adiponectin and Cardiac Structure and Function: The Framingham Offspring Study , 2012, Obesity.

[35]  S. Kihara,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. , 2012, Biochemical and biophysical research communications.

[36]  A. Leite-Moreira,et al.  Physiological, pathological and potential therapeutic roles of adipokines. , 2012, Drug discovery today.

[37]  S. Dudley,et al.  Association of low plasma adiponectin with early diastolic dysfunction. , 2012, Congestive heart failure.

[38]  H. Tse,et al.  Impact of Combination Therapy with Amlodipine and Atorvastatin on Plasma Adiponectin Levels in Hypertensive Patients with Coronary Artery Disease: Combination Therapy and Adiponectin , 2011, Postgraduate medicine.

[39]  D. Pimentel,et al.  Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. , 2011, American journal of physiology. Heart and circulatory physiology.

[40]  F. Liu,et al.  APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. , 2011, Molecular endocrinology.

[41]  Shuilin Huang,et al.  Plasma levels of tumor necrosis factor-&agr; and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase , 2011, Critical care medicine.

[42]  R. DeFronzo,et al.  Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. , 2010, Metabolic syndrome and related disorders.

[43]  A. Beck‐Sickinger,et al.  Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors , 2010, Biological chemistry.

[44]  J. Hare,et al.  Impaired S-Nitrosylation of the Ryanodine Receptor Caused by Xanthine Oxidase Activity Contributes to Calcium Leak in Heart Failure* , 2010, The Journal of Biological Chemistry.

[45]  A. Leite-Moreira,et al.  Physiologic Basis and Pathophysiologic Implications of the Diastolic Properties of the Cardiac Muscle , 2010, Journal of biomedicine & biotechnology.

[46]  D. Teupser,et al.  Lack of Association Between Adiponectin Levels and Atherosclerosis in Mice , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[47]  Luca Scalfi,et al.  Excess Body Weight and Incidence of Stroke: Meta-Analysis of Prospective Studies With 2 Million Participants , 2010, Stroke.

[48]  H. Izawa,et al.  Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy , 2009, Heart.

[49]  Mark J. Kohr,et al.  Nitric oxide signaling and the regulation of myocardial function. , 2008, Journal of molecular and cellular cardiology.

[50]  W. Kosmala,et al.  Plasma levels of TNF-&agr;, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance , 2008, Coronary artery disease.

[51]  C. Morizzo,et al.  Adiponectin and left ventricular structure and function in healthy adults. , 2008, Journal of Clinical Endocrinology and Metabolism.

[52]  B. Goldstein,et al.  Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. , 2008, Cardiovascular research.

[53]  S. Kihara,et al.  Adiponectin Protects Against Angiotensin II–Induced Cardiac Fibrosis Through Activation of PPAR-&agr; , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[54]  MakotoNishida,et al.  Adiponectin Protects Against Angiotensin II–Induced Cardiac Fibrosis Through Activation of PPAR-α , 2008 .

[55]  T. Kadowaki,et al.  Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration , 2008, Diabetologia.

[56]  F. Gao,et al.  Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. , 2007, American journal of physiology. Endocrinology and metabolism.

[57]  K. Tsuda.  ADIPONECTIN AND NITRIC OXIDE PRODUCTION IN NORMOTENSIVE AND HYPERTENSIVE MEN , 2007 .

[58]  J. Díez,et al.  Mechanisms of Cardiac Fibrosis in Hypertension , 2007, Journal of clinical hypertension.

[59]  T. Funahashi,et al.  Pathophysiological significance of adiponectin , 2007, Medical Molecular Morphology.

[60]  S. Kihara,et al.  Adiponectin protects against the development of systolic dysfunction following myocardial infarction. , 2007, Journal of molecular and cellular cardiology.

[61]  K. Walsh,et al.  Adiponectin as an anti-inflammatory factor. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[62]  Walter Koch,et al.  Adiponectin Cardioprotection After Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress , 2007, Circulation.

[63]  D. Tanné,et al.  Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[64]  W. Ricart,et al.  Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. , 2007, The Journal of clinical endocrinology and metabolism.

[65]  Min Zhang,et al.  NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. , 2006, Cardiovascular research.

[66]  J. Whitehead,et al.  Adiponectin – a key adipokine in the metabolic syndrome , 2006, Diabetes, obesity & metabolism.

[67]  A. Leite-Moreira,et al.  Current perspectives in diastolic dysfunction and diastolic heart failure , 2006, Heart.

[68]  U. Müller-Ladner,et al.  Different effects of adiponectin isoforms in human monocytic cells , 2006, Journal of leukocyte biology.

[69]  A. Pfeiffer,et al.  Changes of adiponectin oligomer composition by moderate weight reduction. , 2005, Diabetes.

[70]  G. Watts,et al.  Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia , 2005, Diabetes, obesity & metabolism.

[71]  S. Kihara,et al.  Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. , 2005, American journal of hypertension.

[72]  T. Kadowaki,et al.  Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.

[73]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[74]  Sarah Yoon,et al.  CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. , 2004, Diabetes.

[75]  M. Birnbaum,et al.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. , 2004, The Journal of clinical investigation.

[76]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis in Response to Tissue Ischemia through Stimulation of AMP-activated Protein Kinase Signaling* , 2004, Journal of Biological Chemistry.

[77]  Kazunori Shimada,et al.  Adiponectin and atherosclerotic disease. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[78]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Hui Chen,et al.  Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells* , 2003, Journal of Biological Chemistry.

[80]  T. Funahashi,et al.  Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. , 2003, Diabetes.

[81]  D. Sawyer,et al.  H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. , 2003, Journal of molecular and cellular cardiology.

[82]  J. Engel,et al.  Structure-Function Studies of the Adipocyte-secreted Hormone Acrp30/Adiponectin , 2003, The Journal of Biological Chemistry.

[83]  Pedro Iglesias,et al.  The role of the novel adipocyte-derived hormone adiponectin in human disease. , 2003, European journal of endocrinology.

[84]  NoriyukiOuchi,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[85]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[86]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[87]  P. Anversa,et al.  Loss of intermediate-sized coronary arteries and capillary proliferation after left ventricular failure in rats. , 1991, The American journal of physiology.

[88]  B Rosner,et al.  A prospective study of obesity and risk of coronary heart disease in women. , 1990, The New England journal of medicine.

[89]  M. Alpert,et al.  Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. , 1985, The American journal of cardiology.

[90]  P. Anversa,et al.  Morphometry of Exercise‐Induced Right Ventricular Hypertrophy in the Rat , 1983, Circulation research.

[91]  E. Benjamin,et al.  with The Framingham Offspring Study. , 2018 .

[92]  Ankit Mehra,et al.  Impact of obesity and weight loss on cardiac performance and morphology in adults. , 2014, Progress in cardiovascular diseases.

[93]  L. Lind,et al.  Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women , 2013, Journal of Human Hypertension.

[94]  M. Wilczyńska,et al.  The relationship of carotid arterial stiffness to left ventricular diastolic dysfunction in untreated hypertension. , 2012, Kardiologia polska.

[95]  K. Walsh,et al.  Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. , 2010, Endocrinology.

[96]  W. Miller,et al.  A look between the cardiomyocytes: the extracellular matrix in heart failure. , 2006, Mayo Clinic proceedings.

[97]  W. Colucci,et al.  Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. , 2001, American journal of physiology. Cell physiology.

[98]  D. Sawyer,et al.  MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. , 2001, Journal of molecular and cellular cardiology.

[99]  C A Beltrami,et al.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans. , 1994, Circulation.